Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neurodegeneration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Neurodegeneration. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-001955-29 Sponsor Protocol Number: 024PKAN15004 Start Date*: Information not available in EudraCT
    Sponsor Name:Retrophin, Inc.
    Full Title: Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate replacement therapy, in patients with Pantothenate Kinase-associated Neurodegeneration (PKAN): A Randomized, ...
    Medical condition: Pantothenate kinase associated neurodegeneration (PKAN), an autosomal recessive genetic disorder, the most common form of Neurodegeneration with Brain Iron Accumulation (NBIA). It is a progressive,...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) NO (Completed) FR (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001200-38 Sponsor Protocol Number: 4C-2011-02 Start Date*: 2012-09-07
    Sponsor Name:BCN Peptides S.A.
    Full Title: Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomized controlled trial to assess the efficacy of neuroprotective dru...
    Medical condition: Prevention of neurodegeneration which occurs in Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    15.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002672-12 Sponsor Protocol Number: 73807 Start Date*: 2020-12-11
    Sponsor Name:Erasmus Medical Center
    Full Title: Frontotemporal dementia Imaging of Neuroinflammation, Degeneration and Microglia-Related Effects
    Medical condition: Frontotemporal dementia (FTD), including symptomatic patients and presymptomatic individuals with genetic mutations predisposing to FTD at a later stage in life.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000955-90 Sponsor Protocol Number: renac Start Date*: 2007-04-24
    Sponsor Name:ISTITUTO C. MONDINO
    Full Title: Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple scl...
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003059-56 Sponsor Protocol Number: ICAND Start Date*: 2008-07-29
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: Phase II trial to assess safety and efficacy of Iron chelating agent Deferiprone in patients with Pantothenate Kinase-Associated Neurodegeneration – ICAND – Trial
    Medical condition: PKAN
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042259 Structural brain disorders NEC HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004414-10 Sponsor Protocol Number: TERIFL08519 Start Date*: 2018-02-23
    Sponsor Name:MS Centrum, Department of Neurology, Sshlgrenska University Hospital
    Full Title: Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003001-94 Sponsor Protocol Number: MSGLP Start Date*: 2019-11-06
    Sponsor Name:Lekárska fakulta UK Bratislava
    Full Title: Use of GLP-1 analogs in the treatment of multiple sclerosis
    Medical condition: Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurode...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005860-24 Sponsor Protocol Number: OmniaOMS Start Date*: 2022-10-28
    Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA
    Full Title: Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to Ozanimod in multiple sclerosis
    Medical condition: relapsing remitting multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002481-32 Sponsor Protocol Number: InflamAD Start Date*: 2023-04-11
    Sponsor Name:Amsterdam UMC VUmc
    Full Title: Imaging inflammation in Alzheimer's Disease
    Medical condition: Amyloid-beta positive individuals across the Alzheimer's disease continuum and amyloid-beta negative individuals without cognitive complaints
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004664-22 Sponsor Protocol Number: KS1.1 Start Date*: 2020-06-18
    Sponsor Name:Kuopio University Hospital
    Full Title: Stable Isotope Labeling Kinetics in Normal Pressure Hydrocephalus: implications for neurodegeneration
    Medical condition: Idiopathic normal pressure hydrocephalus (iNPH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029773 Normal pressure hydrocephalus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000891-54 Sponsor Protocol Number: REBOOT-II Start Date*: 2016-11-28
    Sponsor Name:Aging Research Center, Karolinska Institutet and Stockholm University
    Full Title: Effects of enhanced dopaminergic neurotransmission on working memory training efficiency in the healthy elderly - A prospective, single center, randomized, double blind, placebo controlled, paralle...
    Medical condition: No medical condition is under investigation. The project investigates normal age-related decline in intellectual abilities.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005450-30 Sponsor Protocol Number: ABI-MS-P01 Start Date*: 2014-01-08
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
    Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001427-79 Sponsor Protocol Number: TIRCON2012V1-EXT Start Date*: 2015-03-27
    Sponsor Name:ApoPharma Inc.
    Full Title: Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN)
    Medical condition: Pantothenate kinase-associated neurodegeneration (PKAN)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001206-24 Sponsor Protocol Number: 16901 Start Date*: 2007-07-31
    Sponsor Name:UMCG
    Full Title: Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022085-26 Sponsor Protocol Number: rhLAMAN-03 Start Date*: 2010-10-05
    Sponsor Name:Zymenex A/S
    Full Title: A single center, randomized, open-label, multiple-dose study of the efficacy and long-term safety of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alph...
    Medical condition: Treatment of alpha-Mannosidosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000845-11 Sponsor Protocol Number: TIRCON2012V1 Start Date*: 2012-07-16
    Sponsor Name:ApoPharma Inc.
    Full Title: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)
    Medical condition: Pantothenate kinase-associated neurodegeneration (PKAN)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024561-43 Sponsor Protocol Number: 2010-370 Start Date*: 2011-05-24
    Sponsor Name:Scleroseklinikken, Rigshospitalet
    Full Title: Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis
    Medical condition: progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000148-76 Sponsor Protocol Number: 3.0 Start Date*: 2021-08-04
    Sponsor Name:Stockholm Health Care Services
    Full Title: Effects of Montelukast on neuroinflammation in Parkinson's Disease. An open-label single-center trial.
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001629-25 Sponsor Protocol Number: CAIN457B2201E1 Start Date*: 2012-01-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label extension study to evaluate the safety, tolerability and efficacy of AIN457 in patients with relapsing-remitting multiple sclerosis
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002571-24 Sponsor Protocol Number: 15/0118 Start Date*: 2016-10-14
    Sponsor Name:Joint Research Office
    Full Title: A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Diseas...
    Medical condition: Parkinson disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA